Abstract
The last quarter of a century has witnessed remarkable progress in the understanding of phosphoinositide 3-kinases (PI3K) signalling and their involvement in different diseases such as cancer, diabetes and inflammation. Nevertheless, many questions remain open and among these the role of genetic and epigenetic regulation of PI3K isoforms is one of the most prominent. Emerging evidence Indicates that levels of isoforms can be modulated upon stimulation or in both physiological and pathological conditions including increased gene copy number and transcription regulation. In addition, an intriguing role for epigenetic regulation of PI3K expression, caused by mechanisms other than changes in the underlying DNA sequence, are starting to get appreciated. In this review, we summarize the genetic and epigenetic regulation of PI3Ks in physiology and the role played by their alterations in different diseases.
Keywords: PI3K, genetic, epigenetic, cancer, SNP, mutations, regulation
Current Pharmaceutical Design
Title:Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms
Volume: 19 Issue: 4
Author(s): Chanse Fyffe, Richard Buus, Marco Falasca
Affiliation:
Keywords: PI3K, genetic, epigenetic, cancer, SNP, mutations, regulation
Abstract: The last quarter of a century has witnessed remarkable progress in the understanding of phosphoinositide 3-kinases (PI3K) signalling and their involvement in different diseases such as cancer, diabetes and inflammation. Nevertheless, many questions remain open and among these the role of genetic and epigenetic regulation of PI3K isoforms is one of the most prominent. Emerging evidence Indicates that levels of isoforms can be modulated upon stimulation or in both physiological and pathological conditions including increased gene copy number and transcription regulation. In addition, an intriguing role for epigenetic regulation of PI3K expression, caused by mechanisms other than changes in the underlying DNA sequence, are starting to get appreciated. In this review, we summarize the genetic and epigenetic regulation of PI3Ks in physiology and the role played by their alterations in different diseases.
Export Options
About this article
Cite this article as:
Chanse Fyffe, Richard Buus, Marco Falasca , Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms, Current Pharmaceutical Design 2013; 19 (4) . https://dx.doi.org/10.2174/1381612811306040680
DOI https://dx.doi.org/10.2174/1381612811306040680 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Potential Protective Effect of Orange Peel and Selenium against 17β-Estradiol- Induced Chronic Non-Bacterial Prostatitis in Rats
Anti-Cancer Agents in Medicinal Chemistry Prevention of Microbial Communities: Novel Approaches Based Natural Products
Current Pharmaceutical Biotechnology Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design Protein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation
Current Stem Cell Research & Therapy Identification of Phosphoproteins and their Impact as Biomarkers in Cancer Therapeutics
Current Signal Transduction Therapy Curcumin Prevents Brain Damage and Cognitive Dysfunction During Ischemic-reperfusion Through the Regulation of miR-7-5p
Current Neurovascular Research Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer
Current Pharmaceutical Design Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design NEDD4: A Promising Target for Cancer Therapy
Current Cancer Drug Targets Phenolic Compounds in Prevention and Treatment of Skin Cancers: A Review
Current Medicinal Chemistry Nucleosides, a Valuable Chemical Marker for Quality Control in Traditional Chinese Medicine Cordyceps
Recent Patents on Biotechnology Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review
Current Drug Targets Inflammation, Microenvironment, and the Immune System in Cancer Progression
Current Pharmaceutical Design Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets